Integrated Diagnostics and Personalized Care: An Interview With GE Healthcare
To capitalize on the rapidly growing personalized medicine space, large imaging companies have been diversifying and acquiring in companies with molecular diagnostic product lines and pipelines. Medtech Insight recently spoke with two executives from GE Healthcare: Joe Camaratta, general manager, GE Healthcare's Category Solutions and Marketing Group; and Robert Dann, oncology strategic marketing leader, GE Healthcare's Medical Diagnostics Division, who provided some details on the company's overall strategy for personalized medicine and what these developments might mean for the future of patient care.
You may also be interested in...
Pharma is keenly interested in new cancer diagnostics tools, which in many cases are aimed at selecting the best therapy for a specific patient, measuring response to therapy and predicting or more sensitively measuring relapse. These technologies are often the same as those used in pharma's drug development efforts. But deciding with whom and how to ally for the development and distribution of tests is difficult, showing just how uncharted, and bumpy, is the current diagnostics terrain.
Finding growth opportunities in an era of constrained spending and health care reform is not an easy task, but an increasing number of companies operating in the diagnostics space are taking aim at one underserved area they believe will be a big winner in the years ahead: Alzheimer’s disease. This is a field still in its infancy and the risk of failure remains high. But as research progresses, it’s becoming clear that advances in AD diagnostics could play a major role in reducing that risk.
GE is buying Clarient, which provides molecular cancer tests. It intends to make Clarient the cornerstone around which it builds out a molecular in vitro diagnostics business, combining Clarient with its own diagnostic imaging expertise to give it a full suite of triage and cancer diagnostic capabilities. In some ways, it could solve GE's long-standing issue of how to innovate in healthcare and move into high-value businesses without taking on the risks and timelines of pharma-style R&D.